Home » Stocks » ALXO

ALX Oncology Holdings, Inc. (ALXO)

Stock Price: $87.55 USD 7.26 (9.04%)
Updated Mar 1, 2021 3:16 PM EST - Market open
Market Cap 2.98B
Revenue (ttm) 2.40M
Net Income (ttm) n/a
Shares Out 29.66M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 1
Last Price $87.55
Previous Close $80.29
Change ($) 7.26
Change (%) 9.04%
Day's Open 80.86
Day's Range 80.27 - 88.34
Day's Volume 223,133
52-Week Range 28.01 - 117.45

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 month ago

BURLINGAME, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the ...

Seeking Alpha - 1 month ago

ALXO is a South Korea origin oncology concern valued at $3 billion on just phase 1 data. They have just a single asset, a CD47 blocker with some special differences.

Seeking Alpha - 1 month ago

ALX Oncology is developing a drug that encourages macrophages to "eat" targeted cancer cells. Since releasing an IPO in Summer 2020, their share price has more than tripled, despite only havin...

GlobeNewsWire - 1 month ago

BURLINGAME, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the C...

Benzinga - 2 months ago

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider b...

Other stocks mentioned: ATH, BH, GDYN, LXRX, SNEX, SONA, UEPS, UHAL, VTRS
GlobeNewsWire - 2 months ago

BURLINGAME, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD4...

GlobeNewsWire - 2 months ago

BURLINGAME, Calif., Dec. 09, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD4...

GlobeNewsWire - 2 months ago

BURLINGAME, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD4...

About ALXO

ALX Oncology Holdings, a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic used for the treatment of myelodysplastic syndromes and acute myeloid leukemia, as well as a range of solid tumor indications, including head and neck squamous cell and human epidermal growth factor receptor 2 positive gastric/gastroesophageal junction carcinoma. The company was founded in 2015 and is based in Burlingame, California.

Industry
Biotechnology
IPO Date
Jul 17, 2020
CEO
Dr. Jaume Pons Ph.D.
Employees
17
Stock Exchange
NASDAQ
Ticker Symbol
ALXO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for ALXO stock is "Strong Buy." The 12-month stock price forecast is 98.83, which is an increase of 12.88% from the latest price.

Price Target
$98.83
(12.88% upside)
Analyst Consensus: Strong Buy